Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

BACKGROUND: PROMISE-2 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of repeat intravenous (IV) doses of the calcitonin gene-related peptide–targeted monoclonal antibody eptinezumab (ALD403) for migraine prevention in adults with chronic migr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Headache Pain
Main Authors: Silberstein, Stephen, Diamond, Merle, Hindiyeh, Nada A., Biondi, David M., Cady, Roger, Hirman, Joe, Allan, Brent, Pederson, Susan, Schaeffler, Barbara, Smith, Jeff
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Milan 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539382/
https://ncbi.nlm.nih.gov/pubmed/33023473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-020-01186-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados